Latest Biotech News

10x Genomics rolled out the next generation of its Chromium Flex assay, enabling automation‑compatible, plate‑based multiplexing for high‑throughput single‑cell studies. The company said the new...

A STAT feature chronicles Moderna’s post‑pandemic retrenchment, detailing slumping Covid‑vaccine revenues, government contract cancellations, layoffs and a sharp market‑value decline from 2021...

The U.S. Food and Drug Administration unveiled a draft framework proposing to eliminate routine Phase III comparative efficacy trials for biosimilar approvals. The agency, led by Commissioner...

Thermo Fisher Scientific agreed to acquire Clario, a clinical trial software and data solutions company, in a deal worth about $8.9–$9.4 billion in cash. The transaction brings trial management,...

Roche secured global rights to Qyuns Therapeutics’ bispecific antibody QX-031N in a licensing and collaboration that starts with a $75 million upfront payment and reaches up to roughly $1.07...

The U.S. Food and Drug Administration placed a clinical hold on two late‑stage Intellia Therapeutics trials testing a CRISPR-based in vivo gene-editing therapy after a serious liver injury in a...

BridgeBio announced positive Phase III results for two rare‑disease programs, delivering a double win for the company. Encaleret met primary and key secondary endpoints in autosomal dominant...

Eli Lilly and Nvidia announced a collaboration to build what they describe as the most powerful supercomputer operated by a pharmaceutical company, designed to train larger AI models for drug...

Eli Lilly agreed to acquire Adverum Biotechnologies to secure ixoberogene soroparvovec (ixo‑vec), a Phase III one‑time gene therapy candidate for wet age‑related macular degeneration (wAMD). Lilly...

GSK struck a deal to license Empirico’s phase‑1 siRNA candidate EMP‑012, paying $85 million up front and agreeing to up to $745 million in development and commercial milestones. The...

Recursion delivered a phenotypic microglia map to Roche/Genentech under a collaboration and received a $30 million milestone payment, the latest tranche in a multi‑hundred‑million dollar...

10x Genomics introduced a next‑generation Chromium Flex assay that supports automation‑compatible plate‑based multiplexing of up to 384 samples, enabling profiling at scales the company says can...

Thermo Fisher Scientific agreed to acquire Clario in a cash deal that pays roughly $8.9 billion upfront plus contingent consideration, valuing the clinical-trial data and software specialist at up...

The U.S. Food and Drug Administration published draft guidance aiming to streamline biosimilar approvals by no longer routinely requiring head‑to‑head clinical efficacy studies against branded...

Novartis agreed to acquire Avidity Biosciences for about $12 billion to secure three RNA‑based therapies in pivotal testing and Avidity’s delivery platform that aims to expand RNA therapeutics...

Eli Lilly and Nvidia announced a partnership to build what they describe as the most powerful supercomputer owned by a pharmaceutical company, aimed at training larger AI models for drug...

BridgeBio Pharma reported positive top‑line results from a global Phase III trial of encaleret in autosomal dominant hypocalcemia type 1 (ADH1). The company said 76% of treated patients met...

Recursion announced delivery of a whole‑genome microglia phenomap to Roche and Genentech under their multi‑year AI partnership, prompting a $30 million milestone payment and lifting total...

10x Genomics unveiled the next generation of its Chromium Flex assay: an automation‑compatible, plate‑based workflow that enables 384‑sample multiplexing and the capacity to process up to 100...

iOrganBio emerged from stealth with $2 million in seed funding and introduced CellForge, an AI‑driven cell manufacturing platform aimed at producing predictable, reproducible human cells and...